S. Jegham

发表

SSR180711, a Novel Selective α7 Nicotinic Receptor Partial Agonist: (1) Binding and Functional Profile

G. Griebel, O. Bergis, L. Rouquier, 2007, Neuropsychopharmacology.

Molecular interaction between reversible MAO-A inhibitors and the enzyme. Application to aryloxazolidinone, a prototype series.

J. Wouters, F. Ooms, F. Durant, 2000, Neurobiology.

SSR591813, a Novel Selective and Partial α4β2 Nicotinic Receptor Agonist with Potential as an Aid to Smoking Cessation

G. Perrault, P. Soubrié, O. Bergis, 2003, Journal of Pharmacology and Experimental Therapeutics.

SSR591813, a novel selective and partial alpha4beta2 nicotinic receptor agonist with potential as an aid to smoking cessation.

G. Perrault, P. Soubrié, O. Bergis, 2003, The Journal of pharmacology and experimental therapeutics.

Expert Opinion on Therapeutic Patents

S. Jegham, P. George, 1998 .

Reversible inhibition of type B monoamine oxidase. Theoretical study of model diazo heterocylic compound

J. Wouters, F. Ooms, F. Durant, 1997 .

Pilot Scale Process Development of SL65.0102-10, an N-Diazabicyclo[2.2.2]-octylmethyl Benzamide

S. Jegham, P. Liénard, Philippe Gradoz, 2017 .

An enantiospecific synthesis of (+)- and (−)-20-epi-ibophyllidine via an intramolecular diels-alder type cyclization

S. Jegham, B. Das, J. Fourrey, 1989 .

A new route to optically pure cis- and trans-2,5-disubstituted pyrrolidines

S. Jegham, B. Das, 1989 .

A new synthesis of (−)-anisomycin or (+)-anisomycin starting from D-tyrosine or L-tyrosine

S. Jegham, B. Das, 1988 .

A reversible monoamine oxidase A inhibitor, befloxatone: structural approach of its mechanism of action.

J. Wouters, F. Durant, S. Jegham, 1999, Bioorganic & medicinal chemistry.

Antibacterial activities of a few prepared derivatives of oleanolic acid and of other natural triterpenic compounds

H. Jannet, S. Jegham, Z. Mighri, 2003 .

Synthesis and in vivo imaging properties of [11C]befloxatone: a novel highly potent positron emission tomography ligand for mono-amine oxidase-A.

C. Lartizien, O. Curet, Y. Bramoullé, 2003, Bioorganic & medicinal chemistry letters.

SAR103168: a tyrosine kinase inhibitor with therapeutic potential in myeloid leukemias

A. Zilberstein, P. Casellas, M. Levit, 2013, Leukemia & lymphoma.

Mitsunobu N3-alkylation of 1,3,4-oxadiazol-2(3H)-ones

F. Galli, A. Nedelec, A. Lochead, 1999 .

SL65.0155, A Novel 5-Hydroxytryptamine4 Receptor Partial Agonist with Potent Cognition-Enhancing Properties

P. Soubrié, O. Bergis, J. Bockaert, 2002, Journal of Pharmacology and Experimental Therapeutics.

Pharmaceutical compositions containing nicotine and their application into tobacco weaning

B. Scatton, S. Jegham, P. George, 1999 .

Monoamine oxidase A and B inhibitors

S. Jegham, P. George, 1998 .

SL25.1131 [3(S),3a(S)-3-Methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a New, Reversible, and Mixed Inhibitor of Monoamine Oxidase-A and Monoamine Oxidase-B: Biochemical and Behavioral Profile

C. Carter, O. Curet, B. Scatton, 2004, Journal of Pharmacology and Experimental Therapeutics.

Baclofen during alcohol detoxification reduces the need for additional diazepam: a randomized placebo-controlled trial.

C. Crunelle, S. Jegham, F. Matthys, 2023, Alcohol and alcoholism.

Molecular lipophilicity potential by CLIP, a reliable tool for the description of the 3D distribution of lipophilicity: application to 3-phenyloxazolidin-2-one, a prototype series of reversible MAOA inhibitors.

S Collin, F Durant, J. Wouters, 1998, Bioorganic & medicinal chemistry letters.

SL65.0155: a novel 5-HT4 receptor partial agonist with potent cognition enhancing properties

O. Bergis, J. Terranova, R. Fischmeister, 2023 .